ClinicalTrials.gg
Not yet recruitingNCT07298733Updated Dec 23, 2025

The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia

An observational study in Immune Thrombocytopenia and System; Lupus Erythematosus, sponsored by Sohag University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Sohag University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
300
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University — 6 open to participants now, 6 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Sohag University.

Started
2026
with 1 other
Observational
6 of 11
4 open now
Registered
10th of 11
by date

Among the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 10th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Purpura, Thrombocytopenic, Idiopathic by Sohag University, or all of them as a file.
02

Study summary

Primary immune thrombocytopenia (ITP) is an autoimmune- mediated acquired bleeding disorder, defined as a platelet count less than 100×109/L without other causes of isolated thrombocytopenia. The etiology of ITP is complex and heterogeneous, and as no specific biomarkers are indicating its presence, ITP remains a diagnosis of exclusion. The heterogeneous nature of ITP is evident in the differences in clinical presentation and response to regular treatment among patients and the multiple mechanisms that have been forwarded to account for it, such as autoantibodies, T cell dysregulation, and impaired megakaryocytes. Except primary ITP, all forms of immune-mediated thrombocytopenia is defined as secondary ITP. Secondary ITP has several causes, including autoimmune diseases such as systemic lupus erythematosus

Read the detailed description

SLE is a complex autoimmune disease and is usually associated with hematological abnormality , including thrombocytopenia, the prevalence of which in SLE\patients has been reported to be 7-30%. Conversely, the prevalence of SLE in all ITP cases in adults is approximately 5%, making SLE the most common cause of secondary ITP. In the early stages, when there are only thrombocytopenia symptoms, it is sometimes difficult to determine what form of ITP is present in patients with SLE. SLE-associated thrombocytopenia (SLE- TP) is defined as a platelet count less than 100×109/L in the absence of any other identifiable cause.

The pathogenesis of thrombocytopenia in SLE is heterogeneous and multifactorial. However, it is widely accepted that an increased platelet clearance mediated by autoantibodies against platelets contributes to the pathogenesis, which is analogous to the mechanism of ITP. Differing from primary ITP, the clinical treatment for thrombocytopenia secondary to an identifiable cause is often targeted to the ongoing disorder. However, there are no specific biomarkers to differentiate SLE-TP from ITP.

The family of interleukin (IL)-1 cytokines is a family of protein molecules consisting of 11 members, including IL-1α (IL-1F1), IL-1β (IL-1F2), IL-1 receptor antagonist (IL-1Ra, IL-1F3), IL-18 (IL-1F4), IL-36Ra (IL-1F5), IL- 36α (IL-1F6), IL-37 (IL-1F7), IL-36β (IL-1F8), IL-36γ (IL-1F9), IL-38 (IL-1F10), and IL-33 (IL-1F11).

This cytokine family plays a crucial role as major proinflammatory and immunoregulatory mediators in a wide range of autoinflammatory, infectious, tumor, and autoimmune diseases that act through the receptors of the Toll-like/IL-1 receptor superfamily. The production of inflammatory cytokines such as IL-1, IL- 18, and IL-36 acts by activating target cells through the receptor superfamily then amplifying the immune response.

However, antagonists such as IL-1Ra, the receptor antagonist of IL-1α and IL-1β, act as inhibitors of IL-1 dependent inflammation. The blocking of IL-1, particularly of IL-1β, has recently become the standard therapy for autoinflammatory diseases. Moreover, IL-1β, a driver of tumor-promoting inflammation in cancer, can be targeted in patients using an IL-1 receptor antagonist acting as a checkpoint inhibitor. Several studies have suggested abnormal changes in IL-18, and IL-18-binding protein (IL-18BP) were involved in the pathogenesis of SLE and ITP .

Furthermore, recent studies demonstrate that IL-1 may also take part in inflammatory pathologies and auto-immune diseases by participating in the development of T-helper 17 (Th17) cells and increased numbers of Th17 cells have been reported in patients with SLE and ITP.

03

Conditions studied

  • Immune Thrombocytopenia
  • System; Lupus Erythematosus

Keywords

  • gene expression
  • ITP
  • inflammation
  • autoimmune
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

It's a cross sectional study that will be carried out in the period from November 2025 to November 2026.

  • Groups:

    1. Group A: Patients with newly diagnosed or chronic primary ITP.
    2. Group B: Patients with SLE-associated thrombocytopenia.
    3. Group C: Healthy controls (age- and sex-matched).

      Inclusion Criteria:

  • Adults (18-60 years).
  • Diagnosed primary ITP
  • Diagnosed SLE with thrombocytopenia

Exclusion Criteria:

  • Patients on recent immunosuppressive therapy (\<4 weeks).
  • Co-existing infections, malignancies, or other autoimmune cytopenias.

All patients will be subjected to : Sample Collection:

  • 5 ml peripheral blood collected under sterile conditions.
  • Separation of PBMCs (peripheral blood mononuclear cells).

Laboratory Methods:

  1. RNA Extraction: from PBMCs.
  2. cDNA Synthesis: using reverse transcriptase.
  3. Gene Expression Analysis: using Quantitative Real-Time PCR (qRT-PCR)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Adults (18-60 years).

      • Diagnosed primary ITP
      • Diagnosed SLE with thrombocytopenia

Exclusion criteria

Exclusion Criteria:

    • Patients on recent therapy (\<4 weeks).

      • Co-existing infections, , or other cytopenias
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Systemic lupus erythematosis

    patients proved with SLE

    Diagnostic Test: measuring gene expression

  • Idiopathic thrombocytopenic purpura

    patients proved with ITP

    Diagnostic Test: measuring gene expression

  • Normal controls

    normal persons showing no disease matching age and gender

    Diagnostic Test: measuring gene expression

Interventions

  • Diagnostic testmeasuring gene expression

    * 5 ml peripheral blood collected under sterile conditions. * Separation of PBMCs (peripheral blood mononuclear cells). for : 1. RNA Extraction: from PBMCs. 2. cDNA Synthesis: using reverse transcriptase. 3. Gene Expression Analysis using Quantitative Real-Time PCR (qRT-PCR)

06

What researchers measure

Primary outcomes

  1. 1. To evaluate and compare the expression levels of IL-1β and IL-33 in patients with primary ITP and those with SLE-associated thrombocytopenia

    * 5 ml peripheral blood collected under sterile conditions. * Separation of PBMCs (peripheral blood mononuclear cells). Laboratory Methods: 1. RNA Extraction: from PBMCs. 2. cDNA Synthesis: using reverse transcriptase. 3. Gene Expression Analysis: * Quantitative Real-Time PCR (qRT-PCR)

    Time frame: January 2026 to August 2026

  2. 2. To correlate cytokine expression levels with platelet counts and disease activity scores.

    * 5 ml peripheral blood collected under sterile conditions. * Separation of PBMCs (peripheral blood mononuclear cells). Laboratory Methods: 1. RNA Extraction: from PBMCs. 2. cDNA Synthesis: using reverse transcriptase. 3. Gene Expression Analysis: * Quantitative Real-Time PCR (qRT-PCR)

    Time frame: January 2026 to August 2026

  3. 3. To assess the potential of IL-1β and IL-33 as diagnostic biomarkers for differentiating ITP from SLE-thrombocytopenia.

    * 5 ml peripheral blood collected under sterile conditions. * Separation of PBMCs (peripheral blood mononuclear cells). Laboratory Methods: 1. RNA Extraction: from PBMCs. 2. cDNA Synthesis: using reverse transcriptase. 3. Gene Expression Analysis: * Quantitative Real-Time PCR (qRT-PCR)

    Time frame: June 2026 to august 2026

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Aug 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 23, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Aug 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07298733
Lead sponsor
Sohag University
Responsible party
Noha Saber Shafik (Assistant professor, Sohag University) — Principal investigator
First posted
Dec 23, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Aug 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Noha S Shafik, professor
Contact
nohasaber@med.sohag.edu.eg
01067261504
Dina H Mohmad, lecturer
Contact
dinahamada87@yahoo.com
01119886946
Marwa Z elsayed, Lecturer
principal investigator · faculty of Medicine Sohag university
Samar M Kamal, lecturer
study chair · fauculty of Medicine , Sohag university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion